Results 71 to 80 of about 155 (115)

Esketamine Nasal Spray

Pondicherry Journal of Nursing, 2020
Mohamed SJ Farhana, Subbarayan Dhivagar, Subramaniyan Prabavathy   +2 more
openaire   +1 more source

Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine

BMC Psychiatry
Background Treatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US
Carl D. Marci, Kruti Joshi, Stevan Geoffrey Severtson, Janis L. Breeze, Manish K. Jha   +4 more
doaj   +1 more source

Intranasal esketamine plus oral antidepressant for treatment-resistant depression: acute induction and maintenance relapse-prevention outcomes in a systematic review and meta-analysis

Frontiers in Psychiatry
Treatment-resistant depression (TRD) remains a major clinical challenge. Intranasal esketamine, used adjunctively with an oral antidepressant, has been evaluated in randomized trials, but uncertainty persists regarding the magnitude and consistency of ...
Jingqiang Xie, Chunying Pu, Mingyue Sun
doaj   +1 more source

Esketamine nasal spray compassionate use program in the Netherlands: An open label, multi-center cohort study in severe treatment-resistant depression [PDF]

Journal of Affective Disorders Reports
Background: Esketamine, a N-methyl-d-aspartate (NMDA) receptor antagonist, used intranasally (IN), is applied as an antidepressant (AD) in treatment-resistant depressed (TRD) patients. Real-world studies with IN esketamine are still scarce. Objectives: To evaluate the effectiveness and potential moderators of response of IN esketamine in real-world TRD
Abel (K.A.J.) Busz, Emma (E.J.) Schmidt, Rob (R.H.S.) van den Brink, Karen (K.) Foeken, Marasha (M.) de Jong, Joost (J.B.C.) Mertens, Martijn (M.S.) van Noorden, Etienne (E.J.F.L.) Olivier, Koen (K.R.J.) Schruers, Sara (S.I.J.) Schutters, Joris (J.) van Son, Wessel (W.J.) Strootker, Harry (H.C.P.) Venema, Dieuwertje (D.A.) de Waardt, Jasper (J.B.) Zantvoord, Danielle (D.) Cath, Henricus (H.G.) Ruhe   +16 more
openaire   +2 more sources

Cost-effectiveness of esketamine versus alternative treatment strategies for treatment-resistant depression in Hong Kong: A multi-armed modeling study.

PLoS Medicine
BackgroundTreatment-resistant depression (TRD), defined as failure to respond to at least two adequately administered antidepressant (AD) regimens, imposes major clinical and economic burdens.
Yifan Li, Vivien Kin Yi Chan, Mark Jit, Franco Wing Tak Cheng, Hei Hang Edmund Yiu, David Makram Bishai, Dawn Craig, Esther Wai Yin Chan, Sandra Sau Man Chan, Xue Li   +9 more
doaj   +1 more source

Dose-dependent adverse events of esketamine in treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials

Frontiers in Pharmacology
IntroductionThis study systematically evaluated the safety profile of esketamine for treatment-resistant depression through a meta-analysis, focusing on dose-dependent adverse events and associated risk factors to inform precision dosing.MethodsPubMed ...
Yang Qu, Shujin Li, Li Tian, Xiaoxiao Tian, Yongkang Wu, Yongkang Wu   +5 more
doaj   +1 more source

Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention—Mechanisms and Pharmacodynamics

Neuropsychiatric Disease and Treatment
Hui Song,1,* Yang Luo,2,* Lingzhi Fang1 1The Third Hospital of Mianyang, Sichuan Mental Health Center, Mianyang, Sichuan, People’s Republic of China; 2Jiang You Third People Hospital, Mianyang, Sichuan, People’s Republic of China*These ...
Song H, Luo Y, Fang L
doaj  

Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD

European Psychiatry
Background Previous research has demonstrated the positive impact of early remission on disease trajectory for patients with major depressive disorder.
Allan H. Young, Lucie Bartova, Narcís Cardoner, Koen Demyttenaere, Andrea Fagiolini, Yordan Godinov, José Felipe Golib Dzib, Christian von Holt, Roger S. McIntyre, Albino J. Oliveira-Maia, Benoit Rive, Philip Gorwood   +11 more
doaj   +1 more source

Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA

Drugs - Real World Outcomes
Introduction Treatment-resistant depression (TRD) is related to disproportionate unemployment and productivity burden in the USA. The current study describes real-world mental health (MH)-related disability days and costs of patients with TRD initiated ...
Manish K. Jha, Maryia Zhdanava, Aditi Shah, Arthur Voegel, Anabelle Tardif-Samson, Dominic Pilon, Kruti Joshi   +6 more
doaj   +1 more source

A Multi-Center, Open-Label, Single-Arm Study to Investigate the Early Effectiveness of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Using a Mobile Self-Monitoring Application

Pharmaceuticals
This study assesses the early effectiveness of esketamine nasal spray (ESK) in adults with treatment-resistant depression (TRD) 1 day after the first administration, as monitored through self-assessment via the mobile application, Esketamine Continuing ...
Junhyung Kim, Seung-Hoon Lee, Cheolmin Shin, Kyu-Man Han, Sung Joon Cho, Narei Hong, Changsu Han   +6 more
doaj   +1 more source